Related Experiment Video
Updated: Jul 31, 2026
12:29
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Haloprogin: a topical antifungal agent
Applied Microbiology
|May 1, 1970
Summary
Haloprogin effectively treats topical fungal infections in guinea pigs, showing broad-spectrum activity against yeasts and bacteria. It demonstrates comparable antifungal efficacy to tolnaftate but with added antimonilial and antibacterial benefits.
Area of Science:
- Mycology
- Dermatology
- Antimicrobial research
Background:
- Topical mycotic infections require effective antifungal agents.
- Haloprogin and tolnaftate are topical antifungal agents with distinct activity profiles.
Purpose of the Study:
- To evaluate the efficacy of haloprogin against experimentally induced topical mycotic infections.
- To compare the in vitro and in vivo activity spectrum of haloprogin with tolnaftate.
Main Methods:
- Experimental induction of topical mycotic infections in guinea pigs.
- In vitro susceptibility testing against yeasts, Candida species, gram-positive bacteria, and dermatophytes.
- Comparative efficacy assessment with tolnaftate in vivo and in vitro.
Main Results:
- Haloprogin demonstrated high efficacy in treating topical mycotic infections in guinea pigs.
- In vitro, haloprogin was active against yeasts, Candida, and gram-positive bacteria, with antifungal activity comparable to tolnaftate against dermatophytes.
- Haloprogin exhibited significant antimonilial and selective antibacterial activity, unlike tolnaftate.
- Serum reduced haloprogin's in vitro antifungal activity more than tolnaftate's, but topical application showed no diminished efficacy.
Conclusions:
- Haloprogin possesses a broad spectrum of antimicrobial activity, including antifungal, antimonilial, and antibacterial properties.
- Its efficacy against dermatophytes in vivo was not diminished by serum, suggesting clinical potential.
- Haloprogin may be a superior topical agent for treating human dermatophytic and monilial infections.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...